A carregar...
CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations
Melanoma remains a critical public health problem worldwide. Patients with stage IV disease have very poor prognosis and their 1-year survival rate is only 25%. Until recently, systemic treatments with a positive impact on overall survival (OS) had remained elusive. In recent years, the United State...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BlackWell Publishing Ltd
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4430259/ https://ncbi.nlm.nih.gov/pubmed/25619164 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.371 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|